Q32 Bio Inc (QTTB) - Total Liabilities
Based on the latest financial reports, Q32 Bio Inc (QTTB) has total liabilities worth $17.36 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Q32 Bio Inc growing its equity to track the company's year-over-year net asset growth rate.
Q32 Bio Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See Q32 Bio Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Q32 Bio Inc Competitors by Total Liabilities
The table below lists competitors of Q32 Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taiwan IC Packaging
TWO:3372
|
Taiwan | NT$299.21 Million |
|
Aifeex Nexus Acquisition Corporation
NASDAQ:AIFE
|
USA | $1.17 Million |
|
The Platform Group AG
XETRA:TPG
|
Germany | €180.25 Million |
|
Prevas AB
ST:PREV-B
|
Sweden | Skr666.84 Million |
|
Tae Kyung Ind
KO:015890
|
Korea | ₩389.24 Billion |
|
Trans Power Marine Tbk
JK:TPMA
|
Indonesia | Rp2.08 Trillion |
|
KHD Humboldt Wedag International AG
XETRA:KWG
|
Germany | €137.23 Million |
|
LI Ming Development Construction Co Ltd
TWO:6212
|
Taiwan | NT$7.36 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Q32 Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Q32 Bio Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Q32 Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Q32 Bio Inc (2016–2025)
The table below shows the annual total liabilities of Q32 Bio Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.76 Million | -77.20% |
| 2024-12-31 | $86.66 Million | -62.32% |
| 2023-12-31 | $229.98 Million | +19.48% |
| 2022-12-31 | $192.49 Million | +357.54% |
| 2021-12-31 | $42.07 Million | -37.90% |
| 2020-12-31 | $67.74 Million | +30.12% |
| 2019-12-31 | $52.06 Million | -17.02% |
| 2018-12-31 | $62.74 Million | +59.96% |
| 2017-12-31 | $39.22 Million | +483.75% |
| 2016-12-31 | $6.72 Million | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical t… Read more